Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 11/2017

Open Access 01-11-2017 | Magnetic Resonance

Interim heterogeneity changes measured using entropy texture features on T2-weighted MRI at 3.0 T are associated with pathological response to neoadjuvant chemotherapy in primary breast cancer

Authors: Shelley Henderson, Colin Purdie, Caroline Michie, Andrew Evans, Richard Lerski, Marilyn Johnston, Sarah Vinnicombe, Alastair M. Thompson

Published in: European Radiology | Issue 11/2017

Login to get access

Abstract

Objectives

To investigate whether interim changes in hetereogeneity (measured using entropy features) on MRI were associated with pathological residual cancer burden (RCB) at final surgery in patients receiving neoadjuvant chemotherapy (NAC) for primary breast cancer.

Methods

This was a retrospective study of 88 consenting women (age: 30–79 years). Scanning was performed on a 3.0 T MRI scanner prior to NAC (baseline) and after 2–3 cycles of treatment (interim). Entropy was derived from the grey-level co-occurrence matrix, on slice-matched baseline/interim T2-weighted images. Response, assessed using RCB score on surgically resected specimens, was compared statistically with entropy/heterogeneity changes and ROC analysis performed. Association of pCR within each tumour immunophenotype was evaluated.

Results

Mean entropy percent differences between examinations, by response category, were: pCR: 32.8%, RCB-I: 10.5%, RCB-II: 9.7% and RCB-III: 3.0%. Association of ultimate pCR with coarse entropy changes between baseline/interim MRI across all lesions yielded 85.2% accuracy (area under ROC curve: 0.845). Excellent sensitivity/specificity was obtained for pCR prediction within each immunophenotype: ER+: 100%/100%; HER2+: 83.3%/95.7%, TNBC: 87.5%/80.0%.

Conclusions

Lesion T2 heterogeneity changes are associated with response to NAC using RCB scores, particularly for pCR, and can be useful across all immunophenotypes with good diagnostic accuracy.

Key Points

• Texture analysis provides a means of measuring lesion heterogeneity on MRI images.
• Heterogeneity changes between baseline/interim MRI can be linked with ultimate pathological response.
• Heterogeneity changes give good diagnostic accuracy of pCR response across all immunophenotypes.
• Percentage reduction in heterogeneity is associated with pCR with good accuracy and NPV.
Literature
1.
Esserman LJ, Berry DA, Cheang MCU et al (2012) Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012;ACRIN 6657). Breast Cancer Res Treat 132:1049–1062PubMedCrossRef
2.
Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E (2012) Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 48:3342–3354PubMedCrossRef
3.
Hylton NM, Blume JD, Bernreuter WK et al (2012) Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy- results from the ACRIN 6657/I-SPY TRIAL. Radiology 263:663–672PubMedPubMedCentralCrossRef
4.
Loo CE, Straver ME, Rodenhuis S et al (2011) Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 29:660–666PubMedCrossRef
5.
Spring L, Greenup R, Reynolds K, Smith BL, Moy B, Bardia A (2016) Abstract 1439: Pathological complete response after neoadjuvant chemotherapy predicts improved survival in all major subtypes of breast cancer: systematic review and meta-analyses of over 18,000 patients. Cancer Res 76(14 Suppl):1439
6.
Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long term clinical benefit analysis in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172PubMedCrossRef
7.
Minckwitz G, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804CrossRef
8.
Schaefgen B, Mati M, Sinn HP et al (2016) Can routine imaging after neoadjuvant chemotherapy in breast cancer predict pathologic complete response? Ann Surg Oncol 26:789–795CrossRef
9.
la Parra V, Kuerer HM (2016) Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials. Breast Cancer Res 18:28–35CrossRef
10.
Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ (2009) I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86:97–100PubMedCrossRef
11.
Yeh R, Slanetz P, Kopans DB et al (2005) Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 184(3):868–877PubMedCrossRef
12.
De Los SJ, Cantor A, Amos KD et al (2013) Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Cancer 119(10):1776–1783CrossRef
13.
14.
Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW (2005) Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 91:1–10PubMedCrossRef
15.
Partridge SC, Gibbs JE, Lu Y et al (2005) MRI measurement of breast tumour volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 184(6):1774–1781PubMedCrossRef
16.
Pickles MD, Gibbs P, Lowry M, Turnbull LW (2006) Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 24(7):843–847PubMedCrossRef
17.
Castellano G, Bonilha L, Li LM, Cendes F (2004) Texture analysis of medical images. Clin Radiol 59:1061–1069PubMedCrossRef
18.
Nedelec J-F, Yu O, Chambron J, Macher J-P (2004) Texture analysis of the brain: from animal models to human applications. Dialogues Clin Neurosci 6(2):227–233PubMedPubMedCentral
19.
Yu O, Mauss Y, Namer IJ, Chambron J (2001) Existence of contralateral abnormalities revealed by texture analysis in unilateral intractable hippocampal epilepsy. Magn Reson Imaging 19:1305–1310PubMedCrossRef
20.
Gibbs P, Turnbull LW (2003) Textural analysis of contrast-enhanced MR images of the breast. Magn Reson Med 50:92–98PubMedCrossRef
21.
Sinha S, Lucas-Quesada FA, DeBruhl ND et al (1997) Multifeature analysis of Gd-enhanced MR images of breast lesions. J Magn Reson Imaging 7(6):1016–1026PubMedCrossRef
22.
Holli K, Laaperi AL, Harrison L et al (2010) Characterisation of breast cancer types by texture analysis of magnetic resonance images. Acad Radiol 17(2):135–141PubMedCrossRef
23.
Waugh SA, Purdie CA, Jordan LB et al (2016) Magnetic resonance imaging texture analysis classification of primary breast cancer. Eur Radiol 26(2):322–330PubMedCrossRef
24.
Grimm LJ (2016) Breast MRI, radiogenomics: current status and research implications. JMRI 43:1269–1278PubMedCrossRef
25.
Aerts HJWL, Velazquez RE, Leijenaar RTH et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006PubMedCrossRef
26.
Davnall F, Yip CS, Ljungqvist G et al (2012) Assessment of tumour heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging 3:573–589PubMedPubMedCentralCrossRef
27.
O'Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Jackson A (2015) Imaging intratumour heterogeneity: role in therapy response, resistance and clinical outcome. Clin Cancer Res 21:249–257PubMedCrossRef
28.
Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S, Miles K (2012) Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol 22:796–802PubMedCrossRef
29.
Parikh J, Selmi M, Charles-Edwards G et al (2014) Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy. Radiology 272:100–112PubMedCrossRef
30.
Symmans WF, Peintinger F, Hatzis C et al (2007) Measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414–4422PubMedCrossRef
31.
32.
Szczpinski PM, Strzelecki M, Materka A, Klepaczko A (2009) MaZda- a software package for image texture analysis. Comput Methods Programs Biomed 94(1):66–76CrossRef
33.
Haralick RM, Shanmugam K, Dinstein I (1973) Textural features for image classification. IEEE Trans on Syst Man Cybern 3:610–621CrossRef
34.
Mougalian SS, Hernandez M, Lei X et al (2016) Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathological complete response after primary systemic therapy. JAMA Oncol 2:508–516PubMedPubMedCentralCrossRef
35.
Pickles MD, Lowry M, Manton DJ, Turnbull LW (2015) Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicators. Eur Radiol 25:1097–1106PubMedCrossRef
36.
Chen J-H, Nie K, Bahri S et al (2010) Decrease in breast density in the contralateral normal breast of patients receiving neoadjuvant chemotherapy: MR imaging evaluation. Radiology 255:44–52PubMedPubMedCentralCrossRef
37.
O'Sullivan TD, Leproux A, Chen J-H et al (2013) Optical imaging correlates with magnetic resonance imaging breast density and reveals composition changes during neoadjuvant chemotherapy. Breast Cancer Res 15:R14PubMedPubMedCentralCrossRef
38.
Carballido-Gamio J, Link TM, Majumder S (2008) New Techniques for cartilage magnetic resonance imaging relaxation time analysis: texture analysis of flattened cartilage and localised intra- and inter- subject comparisons. Magn Reson Med 59:1472–1477PubMedPubMedCentralCrossRef
39.
Mathias JM, Tofts PS, Losseff NA (1999) Texture analysis of spinal cord pathology in multiple sclerosis. Magn Reson Med 42:929–935PubMedCrossRef
40.
Teruel JR, Heldahl MG, Goa PE et al (2014) Dynamic contrast-enhanced MRI texture analysis for pre-treatment prediction of clinical and pathological response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. NMR Biomed 27:887–896PubMedCrossRef
41.
Michoux N, Van den Broeck S, Lacoste L et al (2015) Texture analysis on MR images help predicting non-response to NAC in breast cancer. BMC Cancer 15:574–586PubMedPubMedCentralCrossRef
42.
Ahmed A, Gibbs P, Pickles M, Turnbull L (2013) Texture analysis in assessment and prediction of chemotherapy response in breast cancer. J Magn Reson Imaging 38:89–101PubMedCrossRef
43.
Flynn E, Collins D, D’Arcy J, Schmidt M, de Souza N (2016) Multi-parametric MRI in the early prediction of response to neo-adjuvant chemotherapy in breast cancer: value of non-modelled parameters. Eur J Radiol 85:837–842CrossRef
44.
Li W, Arasu V, Newitt D et al (2016) Effect of MR imaging contrast thresholds on prediction of neoadjuvant chemotherapy response in breast cancer subtypes: a subgroup analysis of the ACRIN 6657/I-SPY 1 trial. Tomography 2:378–387PubMedPubMedCentralCrossRef
45.
Ring A, Webb A, Ashely S et al (2003) Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? J Clin Oncol 21:4540–4545PubMedCrossRef
46.
Waugh SA, Lerski RA, Bidaut L, Thompson AM (2011) The influence of field strengths and different clinical breast MRI protocols on the outcome of texture analysis using foam phantoms. Med Phys 38:5058–5066PubMedCrossRef
Metadata
Title
Interim heterogeneity changes measured using entropy texture features on T2-weighted MRI at 3.0 T are associated with pathological response to neoadjuvant chemotherapy in primary breast cancer
Authors
Shelley Henderson
Colin Purdie
Caroline Michie
Andrew Evans
Richard Lerski
Marilyn Johnston
Sarah Vinnicombe
Alastair M. Thompson
Publication date
01-11-2017
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 11/2017
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-017-4850-8

Other articles of this Issue 11/2017

European Radiology 11/2017 Go to the issue

Neuro

Linear sign in cystic brain lesions ≥5 mm: A suggestive feature of perivascular space

Oncology

Comparison of a radiomic biomarker with volumetric analysis for decoding tumour phenotypes of lung adenocarcinoma with different disease-specific survival

Urogenital

MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial

Malpractice

How to write an original radiological research manuscript

Magnetic Resonance

Diffusion-weighted imaging of the kidneys in haemolytic uraemic syndrome

Nuclear Medicine

Prognostic implication of the metastatic lesion-to-ovarian cancer standardised uptake value ratio in advanced serous epithelial ovarian cancer